Introduction
============

Esophagus, stomach, small and large intestine, and rectum constitute the digestive tract, which is one of the important parts of the body [@B1]. Gastrointestinal cancer (GIC), including esophageal cancer (EAC), gastric cancer (GC) and colorectal cancer (CRC) represent a major public health problem worldwide [@B2]. Chemotherapy is widely used in many patients with postoperative recurrence or distant metastasis. [@B3], [@B4]. Platinum (oxaliplatin, cisplatin, carboplatin) combined with fluoropyrimidine (5-fluorouacil, capecitabine, S-1) is most commonly used in chemotherapy of GIC [@B3]-[@B7]. However, the effects of chemotherapy vary widely among GIC patients.

More evidence implied that the inter-individual variability of chemotherapy therapeutic efficacy in GIC patients was influenced by genetic factors including *GSTP1*, *GSTT1*, *GSTM1*, *ERCC2*, *ERCC2*, *ABCC2*, *ENOSF1* and *CD24* [@B8]-[@B13]. As a basic regiment to chemotherapy in GIC patients, platinum inhibits DNA synthesis and transcription [@B14].

Although resistance to chemotherapy is multifactorial, the metabolic enzymes of chemotherapeutic drugs play an important role in chemotherapy resistance. As a series of phase II metabolic enzymes, Glutathione S-transferases (GSTs) including GSTM1, GSTP1 and GSTT1 are involved in platinum detoxification [@B15], [@B16]. The effects of *GSTM1*/*GSTT1* (null/present) and *GSTP1* (rs1695, Ile105Val) genetic polymorphisms on chemotherapy efficacy in GIC patients were not consistent in previous research [@B9], [@B13], [@B17]-[@B26].

There were four meta-analyses for the efficacy of glutathione S-transferases (GSTs) variants and chemotherapy in patients with GC or CRC[@B27]-[@B30]. But updated publications were not analyzed in these meta-analyses, which may have biased conclusions. Moreover, there were no meta-analyses of the association between GSTP1 expression and the efficacy of chemotherapy in GC patients. There were no meta-analyses enrolled EAC patients and combined GC, CRC and EAC patients together in meta-analysis. Therefore, we have updated new literatures to investigate the associations between *GSTP1* (Ile105Val), *GSTM1* (null/present), *GSTT1* (null/present) variants and GSTP1 expression and clinical outcomes in GIC patients.

Materials and Methods
=====================

Studies selection
-----------------

All literatures in PubMed, PMC, EMBASE, Web of Science, and Wanfang database until 14th July 2017 were reviewed. Searching key words were "glutathione S-transferase pi 1 or GSTP1", "glutathione S-transferase mu 1 or GSTM1", "glutathione S-transferase theta 1 or GSTT1", "gastrointestinal cancer or carcinoma or tumor", "colorectal cancer or carcinoma or tumor", "esophageal cancer or carcinoma or tumor", "gastric cancer or carcinoma or tumor", "SNPs or genetic polymorphisms or variations", "expression" and "chemotherapy". All literatures were reviewed by Dr. Jian Qu and Yuesheng Sun.

Inclusion and exclusion criteria
--------------------------------

The inclusion criteria in our meta-analysis were as follows: (1) GIC patients including CRC, GC and EAC patients; (2) *GSTP1* IIe105Val variant, GSTP1 expression condition (high and low), and *GSTM1*/*GSTT1* (null /present) variants information; (3) at least having one clinical indicator (ORR, OS, TTP and PFS, ORs and HRs with corresponding to 95% CIs); (4) treatments with chemotherapy details. We excluded publications according: (1) duplicates and irrelevant studies; (2) no data for meta-analysis; (3) meta-analysis or basic research. All authors discussed literature selections that were enrolled in our meta-analysis.

Data processing and quality assessment
--------------------------------------

Two investigators extracted data independently. All authors discussed different opinions on data of each literature. Each literature data includes authors\' names, the year of publication, the country, ethnicity, the number of patients, chemotherapy, median age (years), evaluation criteria, genotyping methods, quality score (QS), and outcomes (ORs or HRs and 95% CIs of ORR, OS, PFS, and TTP). The QS was evaluated independently by Dr. Qiang Qu and Jianghua Pan using previous methods [@B31]. Low quality publication was defined as QS ≤ 14 and high quality was QS \>14.

Statistical analysis
--------------------

Meta-analysis was analyzed by STATA version 12 (Stata Corp, College Station, TX, USA). Heterogeneity was analyzed by Cochrane\'s *Q*-statistic test and *I^2^*test. If*P* \< 0.05 and *I^2^*\> 50%, we defined it as significant heterogeneity, then Mantel-Haenszel random effect model was used in pooling ORs and HRs [@B32]. Z-test was used to analyze the pooled ORs or HRs and statistical significance was accepted if *P* \< 0.05. Egger\'s test and Begg\'s test were used in publication bias and statistical significance was accepted if *P* \< 0.05.

Results
=======

Studies\' characteristics and selection
---------------------------------------

**Figure [1](#F1){ref-type="fig"}** presents the process of research selection. We found 2374 publications after duplicate removal from 5527 publications. We excluded 2324 publications including 1340 irrelevant studies, 39 meta-analyses, 18 case reports, 898 basic studies and 29 studies having no data. Fifty studies including 6518 patients were enrolled for further review. Among them, there were four studies involving in the GSTP1 expression and the chemotherapy efficacy in 264 GIC patients; forty-six studies were enrolled in the meta-analysis of glutathione S-transferase variants (*GSTP1* Ile105Val, *GSTM1*/ *GSTT1* null/present) and chemotherapy efficacy in 6254 GIC patients. Forty-six studies including 6254 patients were selected in investigation about *GSTP1* Ile105Val; 2408 patients in 17 studies were selected in meta-analysis about *GSTM1* null/present variant; and meta-analysis about *GSTT1* null/present variant has 17 studies, including 2414 patients.

The characteristics of author name, the year of publication, the country, the ethnicity, the number of patients, chemotherapy, median age (year), evaluation criterion, genotyping methods, and QS were present in **Table [1](#T1){ref-type="table"}**. Seventeen literatures were conducted on GC patients; 28 literatures were related with CRC patients; 4 literatures were involved in EAC patients and one study was conducted on adenocarcinoma of gastroesophageal junction patients. The detail information of objective response rate (ORR), overall survival (OS), median time to progression (TTP) and median progression-free survival (PFS) in each study is shown in **Table [S1](#SM0){ref-type="supplementary-material"}** and **Table [S2](#SM0){ref-type="supplementary-material"}**.

ORR of GIC patients harboring *GSTP1* Ile105Val variant
-------------------------------------------------------

Thirty-one literatures with 3548 patients were selected for meta-analysis about ORR of GIC patients with *GSTP1* Ile105Val variant. ORR of GIC patients harboring *GSTP1* Ile105Val variants was different (Val carriers *vs.* IIe/IIe: OR=1.58(1.159-2.154), *P*=0.004). Tumor type-subgroup analyses found positive result in CRC patients (OR= 1.761(1.075-2.884), *P*=0.025). Subgroup analyses found association in Asian GIC patients (OR=1.567(1.058-2.319), *P*=0.025) (**Table [2](#T2){ref-type="table"}, Figure [2](#F2){ref-type="fig"}a, 2b**). Subgroup analyses based on other index, such as evaluation criterion, chemotherapy, genotyping method, and quality score present in **Table [S3](#SM0){ref-type="supplementary-material"}**.

Compared with Asian GIC patients harboring *GSTP1* Val105Val genotypic patients, IIe105IIe genotype or IIe carriers have lower ORR (OR=3.400(1.521-7.599),*P*=0.003; OR=3.466 (1.610-7.463), *P*=0.001, separately, **Table [2](#T2){ref-type="table"}**). Moreover, different ORRs in GIC patients harboring different Ile105Val genotype were found (Val/Val *vs.* IIe carriers: OR= 2.256(1.297-3.926), *P*=0.004). Tumor type-subgroup analyses found the association in GC patients (OR=2.279(1.169-4.443), *P*=0.016,**Figure [2](#F2){ref-type="fig"}c, 2d**).

OS of GIC patients harboring *GSTP1* Ile105Val variant
------------------------------------------------------

In order to pooling the HRs of the OS in GIC patients harboring different *GSTP1* Ile105Val genotypes, we selected 21 literatures including 3509 patients. OS of Caucasian GIC patients were different between *GSTP1* IIe/Val genotypic patients and IIe/IIe genotypic patients (HR=0.797(0.674-0.944), *P*=0.009, **Figure [3](#F3){ref-type="fig"}a, Table [3](#T3){ref-type="table"}**).

PFS and TTP of GIC patients harboring *GSTP1* Ile105Val genotypes
-----------------------------------------------------------------

For comparing the PFS, we selected 9 studies having 1378 patients in our meta-analysis. The HRs of PFS in GC or CRC patients harboring different Ile105Val genotypes was different (Val carriers *vs.* IIe/IIe: HR= 1.509(1.059-2.150), *P*=0.023; HR= 0.420(0.247-0.715), *P*=0.001, respectively, **Table [3](#T3){ref-type="table"}, Figure [3](#F3){ref-type="fig"}b**).

In order to compare TTP in GIC patients with different *GSTP1* Ile105Val variants, four publications including 349 patients were enrolled and found no association between Val carriers and IIe/IIe patients (HR= 0.961(0.356-2.591), *P*=0.937). Tumor types or ethnicity subgroup analyses were also negative results (for GC patients: HR= 0.628(0.310-1.274), *P*=0.198; for Asian patients: HR= 0.961(0.356-2.591), *P*=0.937, **Table [3](#T3){ref-type="table"}**).

ORR of GIC patients harboring *GSTM1*/*GSTT1* (null/present) variants
---------------------------------------------------------------------

For comparing ORR in *GSTT1* null/present patients, 10 publications including 1104 patients\' data showed positive result between *GSTT1* null and present patients (OR= 0.657(0.489-0.883), *P*=0.005). Ethnicity- and tumor type-subgroup analyses suggested that, for the Caucasian group, *GSTT1* null/present was associated with ORR (OR= 0.530(0.356-0.789), *P*=0.002); for GC patients, *GSTT1* null/present was associated with ORR (OR=0.643(0.463-0.895), *P*=0.009) (**Table [2](#T2){ref-type="table"}, Figure [3](#F3){ref-type="fig"}c, 3d**).

Our meta-analysis about comparing the ORRs in *GSTM1* null/present patients included 10 literatures with 1102 patients. No association was found between patients harboring *GSTM1* null/present variant and ORRs in GIC patients (OR=1.120 (0.872-1.440), *P*= 0.375). Ethnicity-subgroup and tumor type-subgroup analyses also suggested the negative results (**Table [2](#T2){ref-type="table"}**).

OS and PFS of GIC patients harboring*GSTM1*/*GSTT1* (null/present) variants
---------------------------------------------------------------------------

We compared the pooling OS in *GSTM1* null/present genotypic patients using 7 publications including 892 patients\' data, no statistically significant associations were found in *GSTM1* null/present genotypic patients (HR= 1.001(0.862-1.163), *P*=0.992). No significant difference of OS was found between different *GSTM1* null/present variant patients (**Table [3](#T3){ref-type="table"}**).

We compared the pooling PFS in *GSTM1* null/present genotypic patients using five publications including 996 patients\' data and found no significant association (HR= 0.957(0.823-1.114), *P*=0.572). Ethnicity- and tumor type-subgroup tests also showed negative results (**Table [3](#T3){ref-type="table"}**).

We compared the pooled OS and PFS in *GSTT1* null/present genotypic patients using 8 publications including 1366 patients\' data and found no significant associations (null *vs.* present: HR= 1.104(0.889-1.370), *P*=0.371; HR= 1.102(0.918-1.322),*P*=0.299, respectively). Ethnicity- and tumor type-subgroup tests also showed negative results (**Table [3](#T3){ref-type="table"}**).

ORR and expression level of GSTP1 in GIC patients
-------------------------------------------------

No association was found between GSTP1 expression level and ORR after we pooling data from four publications including 264 patients (low expression *vs.* high expression: OR= 0.854 (0.527-1.384), *P*=0.64). After tumor type-subgroup analysis, GSTP1 expression level and ORR in GC patients were negative results (low expression *vs.* high expression: OR= 0.671 (0.369-1.221),*P*=0.191, **Table [2](#T2){ref-type="table"}**).

Sensitivity analysis
--------------------

Sensitivity analysis found that the OR and HR of every enrolled study didn\'t influence the final significant associations between *GSTP1, GSTM1* and*GSTT1* variants and chemotherapy efficacy in GIC patients (**Figure [S1](#SM0){ref-type="supplementary-material"}**), except the relationship between *GSTP1* (IIe105Val) Val carriers *vs*. IIe/IIe model and the pooled HRs of PFS, which was just two literatures enrolled in tumor type-subgroup analysis.

Moreover, changing the effect models could change the significant association to negative results about *GSTP1* Val/Val *vs.* IIe/IIe and Val/Val *vs.* IIe carriers models and the ORs of ORR in GIC Asian patients (**Figure [S2](#SM0){ref-type="supplementary-material"}**). It implies that the associations between *GSTP1* Val/Val *vs.* IIe/IIe, Val/Val *vs.* IIe carriers and the ORR of GIC Asian patients were not robust.

Publication bias
----------------

Egger\'s test and Begg\'s test was used in Publication bias. As shown in **Figure [S3](#SM0){ref-type="supplementary-material"}**, Begg\'s and Egger\'s funnel plots found no publications bias under *GSTP1* (IIe105Val) any genetic models (all *P\>*0.05,**Figure [S4](#SM0){ref-type="supplementary-material"}**), and under *GSTT1/GSTM1* (null/present) variants (*GSTT1*:*P*=0.788, *P*=0.247,*GSTM1*: P=0.421, *P*=0.272, respectively,**Figure [S5](#SM0){ref-type="supplementary-material"}**).

Begg\'s and Egger\'s tests showed no publication bias in pooling OS analysis among Caucasian genotypic GIC patients under *GSTP1* (IIe105Val) IIe/Val *vs*. IIe/IIe model (*P*=0.421, *P*=0.724, respectively, **Figure [S6](#SM0){ref-type="supplementary-material"}**) and in pooling PFS analysis among GC patients or CRC patients under Val carriers *vs*. IIe/IIe model (*P*=0.317, *P*=0.317, respectively,**Figure [S6](#SM0){ref-type="supplementary-material"}**).

Discussion
==========

We performed a meta-analysis to investigate the association between glutathione S-transferase gene (*GSTP1* (Ile105Val), *GSTM1*/*GSTT1* (null/present) variants and GSTP1 expression and clinical outcomes in patients with GIC. The results showed that Asian GIC patients with *GSTP1* (IIe105Val) Val carriers had better anticancer efficacy than IIe/IIe patients. Caucasian GIC patients carrying the *GSTP1* Val/Val genotype, especially those with stomach disease, have better chemotherapy efficacy than patients with IIe carriers. Caucasian GIC patients bearing IIe/Val genotype have longer survival time than patients with IIe/IIe genotype. Caucasian GIC patients or gastric patients having *GSTT1* present genotype have higher ORR compared to *GSTT1* null genotypic patients. While *GSTM1* present/null variant and the expression level of GSTP1 were not associated with the chemotherapy efficacy to GIC patients. We found that *GSTP1* IIe105Val and *GSTT1* null/present polymorphisms could predict chemotherapy efficacy in GIC patients. Based on the individual genetic profile, the oncologists will have new possibilities to make treatment decisions for their patients, to predictive efficacy of chemotherapy and to redefine scheduling and dosage.

Platinum (oxaliplatin, cisplatin, carboplatin) combined with fluoropyrimidines (5-fluorouacil, capecitabine, S-1) was most commonly used in chemotherapy of gastrointestinal cancers[@B6], [@B33], [@B34]. However, the chemotherapy efficacy of GIC patients is different. Previous studies suggested that variants in *GSTP1*, *GSTM1*, *GSTT1*, *XPCC1*, *MTHFR*, *TYMS* and *ABCC2* influence the chemotherapy efficacy in GC or/and CRC patients [@B5], [@B6], [@B12], [@B34]-[@B36]. *GSTP1*, *GSTM1* and *GSTT1* belong to human glutathione S-transferases super family members and are involved in the inactivation of chemotherapeutic drugs such as platinum through the glutathione metabolic pathway [@B9], [@B28], [@B37]. *GSTP1* IIe105Val and*GSTM1/GSTT1* (null/present) polymorphisms decrease enzyme activity, resulting in the lower intracellular concentration of drugs such as cisplatin [@B29], [@B38]-[@B40]. Therefore, patients harboring *GSTP1* IIe105Val mutant variants may reduce the ability to detoxify drug metabolites, and then have better chemotherapy efficacy.

Our meta-analysis showed that the *GSTP1* IIe105Val variant was associated with ORR of GIC patients (**Table [2](#T2){ref-type="table"}**, **Figure [2](#F2){ref-type="fig"}a, 2b**). Heterogeneity is an important problem in meta-analysis. We also carried out heterogeneity analysis and we found significant heterogeneity when pooling the ORs of ORR in different *GSTP1* IIe105Val variant patients, so we used the Mantel-Haenszel random model to analyze the associations. Changing effect models (Mantel-Haenszel random model and fixed model) didn\'t change the final results. Moreover, sensitivity analysis results found that excluded any studies has no impact on the overall effective size in GIC patients (**Figure [S1](#SM0){ref-type="supplementary-material"}**). GIC is a series of complex cancer diseases. Tumor subtypes, patients\' ethnicity, different chemotherapy regimens and clinical stage may affect the anti-cancer efficacy in GIC patients. Moreover, the evaluation criterion, genotyping method or quality assessment of literatures may also affect the heterogeneity of meta-analysis. Herein, we performed subgroup-analysis according to different evaluation criterion, genotyping methods and quality assessment of literatures. The subgroup-analysis also supported the significant association between *GSTP1* IIe105Val and chemotherapy efficacy in GC and EC patients, or Caucasian GIC patients under dominant genetic model (**Table [2](#T2){ref-type="table"}, Table [S3](#SM0){ref-type="supplementary-material"}**). It implies that tumor type and ethnicity may contribute to the associations. The study-type subgroup analysis showed prospective study groups have no difference between *GSTP1* Val carriers vs. IIe/IIe and ORR of chemotherapy in GIC patients. But there were significant difference on *GSTP1* Val carriers vs. IIe/IIe and ORR of chemotherapy in GIC patients based on retrospective study.

Compared with Asian GIC patients harboring *GSTP1* IIe105IIe genotypes, Val105Val genotypic patients have better response rates to chemotherapy under the fixed model (OR=3.400(1.521-7.599),*P*=0.003, **Table [2](#T2){ref-type="table"}**). However, the random model analysis showed no significant (**Figure [S2](#SM0){ref-type="supplementary-material"}a**), which implied that the positive result was unstable and we could not draw a robust conclusion.

Compared with GIC patients harboring *GSTP1* IIe carriers, Val105Val genotypic patients have better chemotherapy efficacy (**Figure [2](#F2){ref-type="fig"}**). While changing the analytical models could change the significant association of *GSTP1* variants (Val/Val *vs.* IIe carriers) and ORR in Asian GIC patients (**Figure [S2](#SM0){ref-type="supplementary-material"}**). Sensitivity analysis confirmed the positive results (**Figure [S1](#SM0){ref-type="supplementary-material"}**). Tumor type-subgroup analysis showed that, compared with IIe carriers variants, GC patients harboring Val/Val variant, not CRC patients, have better chemotherapy efficacy (**Figure [2](#F2){ref-type="fig"}c, 2d**). Therefore, tumor types and ethnicity both influence the meta-analysis results about *GSTP1* variants (Val/Val *vs.* IIe carriers) and ORR of GIC patients.

We also found that *GSTP1* (Ile105Val) IIe/Val patients had longer survival time than wild-type patients. Exclusion studies did not influence the pooling HR of OS in Caucasian GIC patients. Although significant associations were found between *GSTP1* (Val carriers *vs.* IIe/IIe) and the HRs of PFS in GC or CRC patients, the enrolled studies were two, which could not draw the robust conclusion.

It is the first meta-analysis to investigate the relationship between GSTP1 expression level and anti-cancer efficacy in GIC patients. There were four literatures enrolled for this meta-analysis and we did not find any significant associations. Further updated meta-analysis should be done to confirm our negative results.

Our meta-analysis suggests that GIC patients harboring *GSTT1* present genotype have better chemotherapy efficacy compared to Caucasian patients harboring *GSTT1* null genotype, but not in Asian patients (**Table [2](#T2){ref-type="table"}, Figure [3](#F3){ref-type="fig"}c, 3d**). Subgroup analysis with tumor types showed *GSTT1* null/present variant associated with ORR in GC patients (OR= 0.643(0.463-0.895), *P*=0.009, **Table [2](#T2){ref-type="table"}, Figure [3](#F3){ref-type="fig"}c, 3d**). There was no significant association between *GSTM1* and chemotherapy efficacy. These varies results may be attributed to differences in the distribution of GST families and enzymatic activity of drug detoxification. Our results were consistent with previous meta-analyses, which was just enrolled seven literatures about the *GSTT1* null/present variant and the ORs of ORR in GC patients [@B28].

Heterogeneity and publication bias are important parts of meta-analysis. In order to draw a robust and confidential conclusion, heterogeneity analyzed by Q test and I^2^ statistics; publication bias analyzed by Egger\'s test and Begg\'s test; sensitivity analysis and subgroup analysis were also performed. There were heterogeneities when we pooled ORs or HRs of ORR, OS, PFS and TTP in patients harboring*GSTP1* IIe105Val different variants (**Table [2](#T2){ref-type="table"}, Table [3](#T3){ref-type="table"}**). Therefore, we used fixed and random models to confirm the positive results. We also used subgroup analysis by other index to find the source of heterogeneity. However, there were still heterogeneities after subgroup-analysis (**Table [S3](#SM0){ref-type="supplementary-material"}**). Publication bias test also showed no publication bias (**Figure [S3](#SM0){ref-type="supplementary-material"}**-**S5**).

Previously, there were four meta-analyses involved in Glutathione S-transferases genes\' variants and chemotherapy efficacy in CRC or GC patients [@B27], [@B28], [@B30], [@B36]. No meta-analysis is involved in the association between GSTP1 expression and chemotherapy efficacy in GC patients. No meta-analysis is enrolled with esophageal cancer patients and is combined GC, CRC and EC patients together in analysis. Moreover, previous meta-analyses\' results are conflicting. Therefore, we systematically analyzed all available literatures related to GSTP1 expression levels and *GSTP1* IIe105Val,*GSTM1/GSTT1* deletion variants and chemotherapy efficacy in GIC patients.

There were several limitations about our meta-analysis. First, sample sizes and enrolled studies are still limited. Second, therapeutic indexes such as TTP or PFS were abandoned for analysis. Third, although subgroup analysis, sensitivity analysis, and publication bias were carried out to find the source of heterogeneity, there was still heterogeneity in pooled analysis for *GSTP1*. Fourth, among 50 publications enrolled in the meta-analysis, there were only seven prospective studies. After subgroup-analysis according to tumor type and genetic model, there were less prospective studies to carry out pooling ORs/HRs, or there were publication bias and heterogeneity.

Conclusion
==========

In conclusion, we carried out the meta-analysis including 50 publications with 6518 gastrointestinal cancer patients. We found that *GSTP1* IIe105Val and *GSTT1* deletion variants were associated with chemotherapy efficacy in gastrointestinal cancer patients. A larger sample of further research is needed in different ethnic populations to confirm our conclusions.
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![**Procedure of literature selection.** Figure [1](#F1){ref-type="fig"} present the procedure of literature selection from PubMed, PMC, EMBASE, Web of Science, and Wanfang database.](jcav10p2915g001){#F1}

![**Forest plots of ORR in GIC patients with*GSTP1* IIe105Val variants (Val carriers *vs.* IIe/IIe, Val/Val *vs.* IIe carriers models).** ORs and 95% CI of ORR stratified by (a) tumor types in Val carriers vs. IIe/IIe model; (b) ethnicity in Val carriers vs. IIe/IIe; (c) tumor types in Val/Val *vs.* IIe carriers model; (d) ethnicity in Val/Val *vs.* IIe carriers model.](jcav10p2915g002){#F2}

![**Forest plots of ORR, OS and PFS in GIC patients with*GSTP1* IIe105Val and *GSTT1* null/present variants.** (a) HRs and 95%CI of OS stratified by ethnicity in *GSTP1* IIe105Val IIe/Val *vs.* IIe/IIe model; (b) HRs and 95%CI of PFS stratified by tumor types in *GSTP1* IIe105Val Val carriers *vs*. IIe/IIe model; (c) ORs and 95%CI of ORR stratified by tumor types in *GSTT1* null/present variant; (d) ORs and 95%CI of ORR stratified by ethnicity in *GSTT1* null/present variant.](jcav10p2915g003){#F3}

###### 

Basic information of publications enrolled in meta-analysis

  Author                         Year   Country           Ethnicity          Tumor types   Study type   Patients No.   Chemotherapy                                 Median age (year)   Evaluation criterion   Outcomes       Genotyping method                          Genes               QS
  ------------------------------ ------ ----------------- ------------------ ------------- ------------ -------------- -------------------------------------------- ------------------- ---------------------- -------------- ------------------------------------------ ------------------- ----
  Meulendijks D[@B41]            2016   Mixed             Caucasian          GC            P            185            FU/platinum-based                            59 (27-77)          RECIST                 ORR, PFS, OS   TaqMan assay, PCR-RFLP                     GSTP1               17
  Liu R[@B17]                    2016   China             Asian              GC            R            108            epirubicin/oxaliplatin/ FU                   \-                  RECIST                 ORR,PFS,OS     TaqMan assay                               GSTP1, GSTT1        19
  Liang J[@B19]                  2010   China             Asian              GC            R            85             FU/oxaliplatin                               55(32-77)           NA                     TTP,OS         TaqMan assay                               GSTP1               10
  Li QF[@B20]                    2010   China             Asian              GC            R            89             FU/oxaliplatin                               55(32-77)           NA                     TTP,OS         TaqMan assay                               GSTP1               10
  Shim HJ[@B21]                  2010   Korea             Asian              GC            R            200            taxane and cisplatin                         58 (19-76)          RECIST                 OS,PFS,ORR     TaqMan assay, HRM                          GSTP1,GSTM1.GSTT1   21
  Huang ZH[@B22]                 2009   China             Asian              GC            R            102            FU/oxaliplatin                               58 (34-76)          WHO                    OS             PCR-LDR                                    GSTP1, GSTM1        16
  Ott K[@B23]                    2008   Germany           Caucasian          GC            R            139            cisplatin-based                              57 (47-67)          NA                     OS,TR          TaqMan assay                               GSTP1,GSTM1.GSTT1   11
  Goekkurt E[@B24]               2006   Germany           Caucasian          GC            R            52             FU/cisplatin/FA                              56(27-82)           RECIST                 OS,TR          PCR-RFLP                                   GSTP1,GSTM1.GSTT1   9
  Seo BG[@B25]                   2009   Korea             Asian              GC            R            75             FOLFOX                                       56 (29-84)          RECIST                 ORR            PCR-RFLP                                   GSTP1,GSTM1.GSTT1   12
  Goekkurt E[@B26]               2009   Germany           Caucasian          GC            P            134            platinum-based                               64 (27-86)          NA                     OS,ORR         PCR-RFLP                                   GSTP1,GSTM1.GSTT1   17
  Ruzzo A[@B42]                  2006   Italy             Caucasian          GC            R            175            fluorouracil/cisplatin                       61(38-79)           RECIST                 OS,ORR,PFS     PCR-RFLP                                   GSTP1,GSTM1.GSTT1   16
  Keam B[@B43]                   2008   Korea             Asian              GC            P            73             modified FOLFOX-6                            59 (24-77)          WHO                    OS,ORR         PCR-RFLP                                   GSTP1               15
  Ji M[@B13]                     2013   China             Asian              GC            R            59             docetaxel, cisplatin, and 5-FU               58.6(30-75)         NA                     OS,ORR         PCR-LDR                                    GSTP1               10
  JI YU-ZHI[@B44]                2011   China             Asian              GC            R            80             oxaliplatin‑based                            52 (25-69)          RECIST                 ORR            TaqMan assay                               GSTP1               13
  Kap EJ[@B45]                   2014   Germany           Caucasian          CRC           R            176            oxaliplatin                                  \-                  NA                     OS             Fluorescence-basedmelting curve analysis   GSTP1,GSTM1.GSTT1   15
  Kumamoto K[@B46]               2013   Japan             Asian              CRC           R            63             modified FOLFOX-6                            65(32‑84)           RECIST                 ORR            PCR‑RFLP                                   GSTP1,GSTM1.GSTT1   21
  Lai CY[@B47]                   2013   China             Asian              CRC           R            491            5-FU-Based                                   58.5±12.5           NA                     OS             PCR‑RFLP                                   GSTP1,GSTM1.GSTT1   16
  Bohanes P[@B48]                2015   USA               Caucasian          CRC           R            746            5-FU                                         61(19-86)           NA                     OS             DNA sequencing / PCR-RFLP                  GSTP1               15
  Nishina T[@B49]                2013   Japan             Asian              CRC           P            68             modified FOLFOX-6 + bevacizumab              63(28-81)           RECIST                 ORR            TaqMan                                     GSTP1               16
  Li HY[@B50]                    2012   China             Asian              CRC                        335            FOLFOX6                                      61.5±6.9            NA                     OS             TaqMan                                     GSTP1               18
  Fariña Sarasqueta A(1)[@B51]   2011   the Netherlands   Caucasian          CRC           R            50             fluorouracil/oxaliplatin                     64(30-85)           NA                     ORR            DNA sequencing/ PCR-RFLP                   GSTP1,GSTM1.GSTT1   13
  Fariña Sarasqueta A(2)[@B51]   2011   the Netherlands   Caucasian          CRC           R            42             fluorouracil/leucovorin                      64(30-85)           NA                     ORR            DNA sequencing/PCR-RFLP                    GSTP1,GSTM1.GSTT1   13
  Páez D[@B52]                   2011   Spain             Caucasian          CRC           R            128            5-FU/capecitabine/oxaliplatin                65(32-83)           NA                     ORR            DNA sequencing                             GSTP1               16
  Zarate R[@B53]                 2010   Spain             Caucasian          CRC           R            87             oxaliplatin                                  58(37-75)           RECIST                 ORR/PFS        PCR-RFLP                                   GSTP1,GSTM1.GSTT1   18
  Jones BA[@B54]                 2009   USA               Caucasian          CRC           R            47             5-FU, levamisole, leucovorin, methotrexate   \-                  NA                     OS             PCR-RFLP                                   GSTP1               12
  Le Morvan V(1)[@B55]           2007   France            Caucasian          CRC           R            48             TS inhibiter/irinotecan                      65(45-85)           WHO                    ORR            PCR-RFLP                                   GSTP1               18
  Le Morvan V(2)[@B55]           2007   France            Caucasian          CRC           R            59             TS inhibiter/oxaliplatin                     62(41-86)           WHO                    ORR            PCR-RFLP                                   GSTP1               18
  Stoehlmacher J[@B39]           2004   USA               Caucasian          CRC           R            106            5-FU/oxaliplatin                             60 (24-84)          NA                     TTP            PCR-RFLP                                   GSTP1,GSTM1.GSTT1   13
  Stoehlmacher J[@B56]           2002   USA               mainly Caucasian   CRC           R            107            5-FU/oxaliplatin                             60 (24-83)          NA                     OS             PCR-RFLP                                   GSTP1,GSTM1.GSTT1   13
  Chen Jian Guo[@B57]            2016   China             Asian              CRC           R            60             FOLFOX                                       \-                  WHO                    ORR            PCR-RFLP                                   GSTP1               15
  Dong Ning-ning[@B58]           2014   China             Asian              CRC           R            63             FOLFIRI                                      57 (29-75)          RECIST                 ORR            Sequenom​ Mass ARRAY                       GSTP1               16
  Ying bei-bei[@B59]             2009   China             Asian              CRC           R            102            FOLFOX-4                                     \-                  RECIST                 ORR/TTP        TaqMan-MGB                                 GSTP1               20
  Han-lei[@B60]                  2015   China             Asian              CRC           R            71             modified FOLFOX6                             \-                  RECIST                 ORR            Sequenom​ Mass Array                       GSTP1               16
  Dongya Shen[@B61]              2015   China             Asian              CRC           R            150            FOLFOX                                       \-                  RECIST                 ORR            HRM-SNP                                    GSTP1               18
  Ruzzo[@B62]                    2007   Italy             Caucasian          CRC           R            167            FOLFOX-4                                     66(38-79)           NA                     PFS            PCR-RFLP                                   GSTP1               15
  Liang Jun[@B63]                2009   China             Asian              CRC           R            112            5-FU/oxaliplatin-based                       58 (34-80)          RECIST                 ORR            TaqMan                                     GSTP1               20
  Joerger M[@B64]                2015   The Netherlands   Caucasian          CRC           P            64             capecitabine+oxaliplatin                     58.4(31.7-72.8)     RECIST                 ORR,PFS,OS     DNA sequencing                             GSTP1               22
  Boige V[@B65]                  2010   France            Caucasian          CRC           P            346            LV5FU2/FOLFOX/FOLFIRI                        68(34-83)           WHO                    PFS            PCR/qPCR                                   GSTP1,GSTM1.GSTT1   20
  Yen-Chung Chen[@B66]           2009   China             Asian              CRC           R            166            FOLFOX-4                                     \-                  RECIST                 ORR            PCR-RFLP                                   GSTP1               17
  Hong J[@B67]                   2011   Korea             Asian              CRC           P            52             oxaliplatin + S-1                            63 (37-76)          RECIST                 ORR/PFS        PCR-RFLP                                   GSTP1               15
  Huang MY[@B68]                 2011   China             Asian              CRC           R            157            FOLFOX-4                                     62.5 ± 10.9         NA                     PFS            PCR-RFLP/DNA sequencing                    GSTP1               14
  Lamas MJ[@B69]                 2011   Spain             Caucasian          CRC           R            72             5-FU/oxaliplatin                             66.5 (32-80)        RECIST                 ORR            Snapshot                                   GSTP1               12
  Rumiato E[@B70]                2013   Italy             Caucasian          EAC           R            63             cisplatin/5-FU-based                         62(25-80)           RECIST                 ORR            (ARMS)-PCR,PCR-RFLP                        GSTP1,GSTM1.GSTT1   15
  Wang Y[@B71]                   2011   China             Asian              EAC           R            256            cisplatin-based                              \-                  RECIST                 ORR            DNA sequencing                             GSTP1               16
  Gui Yan[@B72]                  2016   China             Asian              EAC           R            168            5-FU and cisplatin                           \-                  RECIST                 ORR,OS         DNA sequencing                             GSTP1               17
  Joerger M[@B64]                2015   The Netherlands   Caucasian          EAC           R            76             capecitabine+cisplatin+epirubicin            57.2(35-75.3)       RECIST                 ORR,OS         DNA sequencing                             GSTP1               22
  Kwon HC[@B73]                  2007   Korea             Asian              GC            R            64             5-FU/oxaliplatin                             51(31-74)           RECIST                 expression     immunohistochemistry                       GSTP1               18
  Boku N[@B74]                   2007   Japan             Asian              GC            R            66             5-FU/cisplatin                               63 (19-75)          WHO                    expression     immunohistochemistry                       GSTP1               20
  In Sil Choi[@B75]              2011   Korea             Asian              GC            R            41             S-1 plus cisplatin                           62 (33-73)          RECIST                 expression     immunohistochemistry                       GSTP1               16
  Li S[@B76]                     2017   China             Asian              AGEJ          R            93             oxaliplatin based                            66.6(40-76)         RECIST                 expression     immunohistochemistry                       GSTP1               18

NR: not reported; QS, quality score; HR: hazard ratio; ORR: objective response rate; OS, overall survival; PFS, progression-free survival; MST, median survival time; TTP, time to progression; PCR, polymerase chain reaction; PCR-RFLP, PCR-restriction fragment length polymorphism; RECIST, Response Evaluation Criteria in Solid Tumors; WHO, World Health Organization; PCR-LDR, PCR-ligase detection reaction; PCR-CTPP, duplex PCR with the confronting-two-pair primer; HRM, high resolution melt; 5-FU, 5-fluorouracil; FOLFOX, leucovorin+5-fluorouracil+oxaliplatin; TS, thymidylate synthase; FOLFIRI, leucovorin+5-fluorouracil+irinotecan; LV5FU2, leucovorin+5-fluorouracil; EAC , esophageal cancer; GC, gastric cancer; CRC , colorectal cancer; AGEJ, Adenocarcinoma of Gastroesophageal Junction. P, prospective study; R, retrospective study.

###### 

The pooling ORs of ORR in GIC patients with different *GSTP1* IIe105Val, *GSTM1*/*GSTT1* variants and GSTP1 expression levels.

  Genetic comparisons          No. of studies   Study groups   Test of association             Test of heterogeneity                                   
  ---------------------------- ---------------- -------------- ------------------------ ------ ----------------------- --- -------- --------- -------- --------
  *GSTP1*                                                                                                                                              
  Val carriers *vs.* IIe/IIe   31               Overall        **1.580(1.159-2.154)**   2.9    **0.004**               R   102.39   \<0.001   70.70%   0.5184
                               11               GC             1.598(0.998-2.560)       1.95   0.051                   R   31.75    \<0.001   68.50%   0.4165
                               16               CRC            **1.761(1.075-2.884)**   2.25   **0.025**               R   53.12    \<0.001   71.80%   0.702
                               4                EAC            1.080(0.482-2.418)       0.19   0.852                   R   13.16    0.004     77.20%   0.5119
                               20               Asian          **1.567(1.058-2.319)**   2.24   **0.025**               R   69.3     \<0.001   72.60%   0.554
                               11               Caucasian      1.607(0.944-2.736)       1.75   0.08                    R   33.1     \<0.001   69.80%   0.5374
  Val/Val *vs.* IIe/IIe        14               Overall        2.265(0.937-5.475)       1.82   0.069                   R   52.01    \<0.001   75.00%   1.9912
                               8                GC             1.982(0.599-6.563)       1.12   0.263                   R   36.26    \<0.001   80.70%   2.2709
                               4                CRC            3.151(0.315-31.545)      0.98   0.329                   R   13.75    0.003     78.20%   4.248
                               2                EAC            2.480(0.784-7.842)       1.55   0.122                   F   1.5      0.22      33.50%   \-
                               5                Asian          **3.400(1.521-7.599)**   2.98   **0.003**               F   8.11     0.088     50.70%   \-
                               9                Caucasian      2.059(0.661-6.412)       1.25   0.213                   R   41.28    \<0.001   80.60%   2.3382
  IIe/Val *vs.* IIe/IIe        14               Overall        1.130(0.607-2.103)       0.38   0.701                   R   69.89    \<0.001   81.40%   1.0835
                               8                GC             0.825(0.347-1.961)       0.44   0.663                   R   48.96    \<0.001   85.70%   1.2721
                               4                CRC            2.780(0.710-10.892)      1.47   0.142                   R   14.58    0.002     79.40%   1.51
                               2                EAC            0.845(0.415-1.721)       0.46   0.642                   F   2.44     0.118     59.10%   \-
                               5                Asian          1.270(0.836-1.929)       1.12   0.263                   F   8.23     0.083     51.40%   \-
                               9                Caucasian      1.061(0.420-2.677)       0.12   0.901                   R   61.01    \<0.001   86.90%   1.6738
  Val/Val *vs.* IIe carriers   15               Overall        **2.256(1.297-3.926)**   2.88   **0.004**               R   29.71    0.008     52.90%   0.5742
                               8                GC             **2.279(1.169-4.443)**   2.42   **0.016**               R   18.72    0.016     57.30%   0.5481
                               4                CRC            1.991(0.325-12.197)      0.74   0.457                   R   10.1     0.018     70.30%   2.3401
                               2                EAC            2.715(0.890-8.285)       1.76   0.079                   F   0.68     0.409     0.00%    \-
                               5                Asian          **3.466(1.610-7.463)**   3.18   **0.001**               F   7.9      0.095     49.30%   \-
                               9                Caucasian      **2.011(1.324-3.052)**   3.28   **0.026**               R   19.65    0.02      54.20%   0.5014
  *GSTT1* Null vs. Present     10               Overall        **0.657(0.489-0.883)**   2.78   **0.005**               F   5.86     0.753     0.00%    \-
                               7                GC             **0.643(0.463-0.895)**   2.62   **0.009**               F   3.57     0.735     0.00%    \-
                               2                CRC            1.014(0.447-2.302)       0.03   0.973                   F   0.17     0.68      0.00%    \-
                               3                Asian          0.873(0.557-1.368)       0.59   0.553                   F   0.29     0.865     0.00%    \-
                               7                Caucasian      **0.530(0.356-0.789)**   3.13   **0.002**               F   2.96     0.814     0.00%    \-
  *GSTM1* Null vs. Present     10               Overall        1.120(0.872-1.440)       0.89   0.375                   F   6.29     0.71      0.00%    \-
                               7                GC             1.209(0.918-1.593)       1.35   0.177                   F   3.07     0.8       0.00%    \-
                               2                CRC            0.772(0.351-1.701)       0.64   0.521                   F   1.58     0.209     36.50%   \-
                               3                Asian          1.067(0.669-1.700)       0.27   0.786                   F   0.07     0.966     0.00%    \-
                               7                Caucasian      1.143(0.849-1.540)       0.88   0.379                   F   6.15     0.406     2.50%    \-
  GSTP1 expression             4                Overall        0.854(0.527-1.384)       0.64   0.521                   F   7.5      5.70%     60.00%   \-
                               3                GC             0.671(0.369-1.221)       1.31   0.191                   F   5.74     5.70%     65.20%   \-

OR, odds ratio; HR: hazard ratio; CI, confidence interval; vs., versus; F, fixed effect model; R, random effect model.

###### 

The pooling HRs of OS, PFS and TTP in GIC patients with different *GSTP1* IIe105Val and *GSTM1*/*GSTT1* variants.

  Genetic comparisons          No. of studies   Study groups   Test of association             Test of heterogeneity                                  
  ---------------------------- ---------------- -------------- ------------------------ ------ ----------------------- --- ------- --------- -------- --------
  *GSTP1*-OS                                                                                                                                          
  Val carriers *vs.* IIe/IIe   10               Overall        0.903(0.613-1.332)       0.51   0.608                   R   48.2    \<0.001   81.30%   0.3021
                               5                GC             0.797(0.437-1.455)       0.74   0.461                   R   24.64   \<0.001   83.80%   0.3891
                               4                CRC            0.967(0.515-1.819)       0.1    0.918                   R   14.89   0.002     79.90%   0.3181
                               7                Asian          0.975(0.606-1.569)       0.11   0.916                   R   41.13   \<0.001   85.40%   0.3385
                               3                Caucasian      0.738(0.347-1.570)       0.79   0.43                    R   6.56    0.038     69.50%   0.3093
  IIe/Val*vs.* IIe/IIe         13               Overall        0.900(0.794-1.020)       1.65   0.098                   F   18.31   0.107     34.50%   \-
                               11               CRC            0.878(0.763-1.010)       1.83   0.068                   F   16.37   0.089     38.90%   \-
                               3                Asian          1.044(0.865-1.259)       0.45   0.655                   F   1.34    0.512     0.00%    \-
                               10               Caucasian      **0.797(0.674-0.944)**   2.63   **0.009**               F   12.59   0.182     28.50%   \-
  Val/Val *vs.* IIe/IIe        13               Overall        0.646(0.398-1.046)       1.78   0.076                   R   43.88   \<0.001   72.70%   0.5021
                               11               CRC            0.619(0.342-1.120)       1.59   0.113                   R   43.59   \<0.001   77.10%   0.6777
                               3                Asian          0.774(0.495-1.210)       1.13   0.216                   F   2.86    0.239     30%      \-
                               10               Caucasian      0.605(0.315-1.164)       1.51   0.132                   R   40.86   \<0.001   78.00%   0.7601
  *GSTP1*-PFS                                                                                                                                         
  Val carriers *vs.* IIe/IIe   4                Overall        0.855(0.410-1.781)       0.42   0.675                   R   17.22   0.001     82.60%   0.4565
                               2                GC             **1.509(1.059-2.150)**   2.28   **0.023**               F   1.7     0.192     41.30%   \-
                               2                CRC            **0.420(0.247-0.715)**   3.19   **0.001**               F   0.13    0.714     0.00%    \-
                               3                Asian          1.115(0.552-2.253)       0.3    0.762                   R   8.54    0.014     76.60%   0.2913
  IIe/Val *vs.* IIe/IIe        5                Overall        0.990(0.827-1.185)       0.11   0.911                   F   3.97    0.41      0.00%    \-
                               4                CRC            0.978(0.790-1.210)       0.21   0.835                   F   3.92    0.27      23.50%   \-
                               2                Asian          0.996(0.719-1.379)       0.03   0.979                   F   0.47    0.493     0.00%    \-
                               3                Caucasian      0.987(0.796-1.225)       0.12   0.907                   F   3.49    0.174     42.80%   \-
  Val/Val *vs.* IIe/IIe        5                Overall        0.709(0.384-1.308)       1.1    0.27                    R   16.5    0.002     75.80%   0.3262
                               4                CRC            0.664(0.306-1.441)       1.04   0.3                     R   16.49   0.001     81.80%   0.4454
                               2                Asian          0.759(0.367-1.570)       0.74   0.457                   F   0.55    0.459     0.00%    \-
                               3                Caucasian      0.707(0.306-1.638)       0.81   0.419                   R   15.79   \<0.001   87.30%   0.4745
  *GSTP1*-TTP                                                                                                                                         
  Val carriers *vs.* IIe/IIe   4                Overall        0.961(0.356-2.591)       0.08   0.937                   R   43.02   \<0.001   93.00%   0.9525
                               3                GC             0.628(0.310-1.274)       1.29   0.198                   R   10.03   0.007     80.10%   0.3121
                               4                Asian          0.961(0.356-2.591)       0.08   0.937                   R   43.02   \<0.001   93.00%   0.9525
  *GSTT1*-PFS                  5                Overall        1.102(0.918-1.322)       1.04   0.299                   F   1.42    0.841     0.00%    \-
                               3                GC             1.017(0.807-1.282)       0.14   0.885                   F   0.2     0.904     0.00%    \-
                               2                CRC            1.257(0.934-1.692)       1.51   0.132                   F   0       0.963     0.00%    \-
                               4                Caucasian      1.178(0.937-1.480)       1.4    0.161                   F   0.52    0.915     0        \-
  *GSTT1*-OS                   8                Overall        1.104(0.889-1.370)       0.89   0.371                   R   15.36   0.032     54.40%   0.0482
                               4                GC             1.136(0.689-1.872)       0.5    0.618                   R   8.83    0.012     77.40%   0.1492
                               4                CRC            0.998(0.844-1.180)       0.03   0.979                   F   4.32    0.229     30.50%   \-
  *GSTM1*-PFS                  5                Overall        0.957(0.823-1.114)       0.57   0.572                   F   1.96    0.743     0.00%    \-
                               3                GC             1.034(0.838-1.275)       0.31   0.755                   F   0.88    0.645     0.00%    \-
                               2                CRC            0.880(0.707-1.095)       1.14   0.253                   F   0       1         0.00%    \-
                               2                Asian          1.054(0.810-1.371)       0.39   0.695                   F   0.82    0.365     0.00%    \-
                               3                Caucasian      0.913(0.758-1.098)       0.97   0.333                   F   0.37    0.83      0.00%    \-
  *GSTM1*-OS                   7                Overall        1.001(0.862-1.163)       0.01   0.992                   F   5.74    0.453     0.00%    \-
                               3                GC             1.103(0.889-1.368)       0.89   0.372                   F   1.14    0.565     0.00%    \-
                               3                CRC            0.900(0.722-1.121)       0.94   0.346                   F   2.89    0.236     30.80%   \-
                               2                Asian          1.174(0.891-1.545)       1.14   0.254                   F   0.64    0.424     0.00%    \-
                               5                Caucasian      0.936(0.783-1.119)       0.73   0.466                   F   3.27    0.514     0.00%    \-

OR, odds ratio; HR: hazard ratio; CI, confidence interval; vs., versus; F, fixed effect model; R, random effect model.
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